All In Biotech

Free tool

FAERS Monitor: Ceretec

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019829 or its brand name (Ceretec, Technetium Tc-99m Exametazime Kit). Reports on generic versions are filed under their own applications.

Reports

38

Serious

14

37% of reports

Hospitalization

3

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event13
  • drug ineffective8
  • radioisotope scan abnormal7
  • headache4
  • rash4
  • chills3
  • condition aggravated2
  • dyspnoea2
  • malaise2
  • nausea2
  • unresponsive to stimuli2
  • vasospasm2
  • abdominal discomfort1
  • anaphylactic reaction1
  • autoimmune thyroiditis1

Reports by year received

View as table
YearReports
20041
20061
20143
20152
20166
20174
20182
20192
20206
20212
20223
20242
20252
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,121 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
radioisotope scan abnormalSignal75540.62826.133,098
vasospasm21208.4313.11,354
autoimmune thyroiditis1146.521.236
unresponsive to stimuli242.911.145
no adverse eventSignal1339.725.6457
chillsSignal314.24.825
anaphylactic reaction110.01.42
rashSignal45.12.010
condition aggravated23.60.92
headacheSignal43.51.45
drug ineffectiveSignal83.41.812
abdominal discomfort13.30.50
malaise22.50.71
dyspnoea22.00.50
nausea21.40.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.